NEU Stock Overview
A biopharmaceutical company, develops drugs for the treatment of neurological disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for NEU from our risk checks.
Neuren Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$9.19 |
| 52 Week High | AU$24.00 |
| 52 Week Low | AU$8.61 |
| Beta | 1.85 |
| 1 Month Change | -21.32% |
| 3 Month Change | -22.45% |
| 1 Year Change | -55.73% |
| 3 Year Change | 132.07% |
| 5 Year Change | 429.68% |
| Change since IPO | 24.19% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of Neuren Pharmaceuticals Limited's (ASX:NEU) Tunnel
Apr 01
A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 06Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching
Jan 15New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Nov 11Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 08Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Oct 24Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04
Shareholder Returns
| NEU | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -6.8% | -5.0% | 0.08% |
| 1Y | -55.7% | -33.1% | -3.9% |
Return vs Industry: NEU underperformed the Australian Pharmaceuticals industry which returned -33.1% over the past year.
Return vs Market: NEU underperformed the Australian Market which returned -3.9% over the past year.
Price Volatility
| NEU volatility | |
|---|---|
| NEU Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 16.3% |
| 10% least volatile stocks in AU Market | 4.0% |
Stable Share Price: NEU has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: NEU's weekly volatility (9%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Jon Pilcher | www.neurenpharma.com |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins.
Neuren Pharmaceuticals Limited Fundamentals Summary
| NEU fundamental statistics | |
|---|---|
| Market cap | AU$1.16b |
| Earnings (TTM) | AU$142.04m |
| Revenue (TTM) | AU$216.83m |
8.2x
P/E Ratio5.3x
P/S RatioIs NEU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEU income statement (TTM) | |
|---|---|
| Revenue | AU$216.83m |
| Cost of Revenue | AU$32.97m |
| Gross Profit | AU$183.86m |
| Other Expenses | AU$41.82m |
| Earnings | AU$142.04m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.13 |
| Gross Margin | 84.79% |
| Net Profit Margin | 65.51% |
| Debt/Equity Ratio | 0% |
How did NEU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 21:32 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuren Pharmaceuticals Limited is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |